An interventional study of Intracameral injection and Intravitreal injection in Glaucoma, Neovascular and Vascular Endothelial Growth Factor Overexpression, sponsored by Prince of Songkla University. Recruiting at 1 site in Thailand. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-21.
Sponsored by Prince of Songkla University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
To prospect studying the efficacy and safety of treating NVG with the intracameral versus the intravitreal injection of Bevacizumab.
The present study comparing the safety and efficacy of 1.25mg/0.05mL Bevacizumab injection via the intracameral route versus the intravitreal route in treating the neovascular glaucoma
39 studies on the registry are indexed under Glaucoma, Neovascular; 5 are open to participants now.
This study's planned enrollment of 40 is close to the median of 40 across 32 interventional studies indexed under Glaucoma, Neovascular.
Browse Glaucoma, Neovascular studies →Prince of Songkla University is the lead sponsor of 116 studies on the registry; 13 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Intracameral Bevacizumab 1.25 mg/0.05 mL. Injection
Procedure: Intracameral injection
Intravitreal Bevacizumab 1.25 mg/0.05 mL. Injection
Procedure: Intravitreal injection
A/C injection of 1.25 mg/0.05 mL bevacizumab
Vitreous injection of 1.25 mg/0.05 mL bevacizumab
regression of nevolascularization
Amount of nevolascular of iris and angle regression
Time frame: 2 months
IOP reduction
IOP reduction at 2-month visit compare to baseline
Time frame: 2 months
Injection complication
Hyphema, IOP spike
Time frame: 2 days
Plan to share: No
No publications or documents are linked to this record.
Started Aug 2018 (actual). Primary completion is estimated for Jul 2026, 95 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Prince of Songkla University →